Journals / Ulusal Travma ve Acil Cerrahi Dergisi / 2022 / Cilt: 28 - Sayı: 6

Preventive effect of fucoxanthin administration on intra- abdominal adhesion: An experimental animal study

Pages
743–750
Publication Date
2022-11-07
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Adhesion was significantly less macroscopically in the Fx group compared to the control and sham group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND: The most common cause of intra-abdominal adhesion (IAA) is previous abdominal surgery and mortality.
📊
Key Findings & Data:Approximately 3% of all laparotomies are related to adhesions.
💡
Conclusion & Impact:Adhesion was significantly less macroscopically in the Fx group compared to the control and sham group (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

BACKGROUND: The most common cause of intra-abdominal adhesion (IAA) is previous abdominal surgery and mortality. IAA can cause serious complications such as chronic abdominal pain, ileus, and infertility. Approximately 3% of all laparotomies are related to adhesions. IAA reduces the quality of life of the patient, causes morbidity, and increases health expenditures. In this study, we aimed to investigate the preventive effect of fucoxanthin (Fx) on IAA in the intra-abdominal surgical adhesion model that experimentally created in rats. METHODS: This study used 21 Sprague-Dawley rats divided into three groups. After anesthesia, the abdomen was opened, the cecum and right abdominal wall were damaged with a sterile toothbrush until petechiae bleeding was seen. No additional action was taken to the control group. In the sham group, 5 cc saline solution was released into the peritoneum before the abdomen was closed. In the Fx group, 35 mg/kg Fx was instilled intraperitoneally and the abdomen was closed. On the 21 st post-operative day, all subjects were anesthetized with standard anesthesia. Macroscopic adhesions were quantitatively evaluated according to the Mazuji classifica- tion. The cecum anterior wall and parietal peritoneum were excised for pathological sampling. A pathologist, unaware of the groups, evaluated inflammation, fibroblastic activity, and vascular proliferation. In addition, serum tumor necrosis factor-alpha (TNF-α) and interleukin-10 levels were measured. RESULTS: No rat was lost during the study period. Congenital adhesion was not observed in any of the subjects at the first laparo- tomy. Adhesion was significantly less macroscopically in the Fx group compared to the control and sham group (p

🔖

Cite This Article

Dalbaşı, E., Tüzün, A., Arserim, N. B., Özcan, F., Dogan, E., Çetin, A. (2022). Preventive effect of fucoxanthin administration on intra- abdominal adhesion: An experimental animal study. Ulusal Travma ve Acil Cerrahi Dergisi, Cilt: 28 - Sayı: 6, 743–750. https://ajindex.com/articles/655415

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Beyene RT, Kavalukas SL, Barbul A. Intra-abdominal adhesions: Anatomy, physiology, pathophysiology, and treatment. Curr Probl Surg 2015;52:271–319
  2. Holmdahl L, Ericsson E, Ericsson BI, Risberg B. Depression of peri- toneal fibrinolysis during operation is a local response to trauma. Surgery 1998;13:539–44
  3. Moris D, Chakedis J, Rahnemai-Azar AA, Wilson A, Hennessy MM, Athanasiou A, et al. Postoperative abdominal adhesions: Clinical signif- icance and advances in prevention and management. J Gastrointest Surg 2017;21:1713–22
  4. Ward BC, Panitch A. Abdominal adhesions: Current and novel therapies. J Surg Res 2011;165:91–111
  5. Wallwiener M, Brucker S, Hierlemann H, Brochhausen C, Solomayer E, Wallwiener C. Innovative barriers for peritoneal adhesion prevention: Liquid or solid? A rat uterine horn model. Fertil Steril 2006;86 Suppl 4:1266–76
  6. Trew G. Postoperative adhesions and their prevention. Rev Gynaecol Perinat Pract 2006;6:47–56
  7. Satomi Y. Antitumor and cancer-preventative function of fucoxanthin: A marine carotenoid. Anticancer Res 2017;37:1557–62
  8. Arumugam V, Venkatesan M, Ramachandran S, Sundaresan U. Bioactive peptides from marine ascidians and future drug development-A review. Int J Pept Res Ther 2017;24:13–18
  9. Altınel Y, Taşpınar E, Ozgüç H, Oztürk E, Akyıldız EU, Bağdaş D. The protective effect of clinoleic against post-surgical adhesions. Ulus Travma Acil Cerrahi Derg 2014;20:16
  10. Yan S, Yue Y, Zeng L, Jiang C, Li W, Li H, et al. Ligustrazine nanopar- ticles nano spray’s activation on Nrf2/ARE pathway in oxidative stress injury in rats with postoperative abdominal adhesion. Ann Transl Med 2019;7:379
  11. Lu S, Hu W, Zhang Z, Ji Z, Zhang T. Sirolimus-coated, poly(L-lactic acid)-modified polypropylene mesh with minimal intra-peritoneal adhe- sion formation in a rat model. Hernia 2018;22:1051–60
  12. Liu M, Li W, Chen Y, Wan X, Wang J. Fucoxanthin: A promis- ing compound for human inflammation-related diseases. Life Sci 2020;255:117850
  13. Wang J, Ma Y, Yang J, Jin L, Gao Z, Xue L, et al. Fucoxanthin inhibits tu- mour-related lymphangiogenesis and growth of breast cancer. J Cell Mol Med 2019;23:2219–29
  14. Maeda H, Kanno S, Kodate M, Hosokawa M, Miyashita K. Fucoxanthi- nol, metabolite of fucoxanthin, ımproves obesity-ınduced ınflammation in adipocyte cells. Mar Drugs 2015;13:4799–813
  15. Zheng J, Tian X, Zhang W, Zheng P, Huang F, Ding G, et al. Protective effects of fucoxanthin against alcoholic liver ınjury by activat